Earnings Ahead

EXEL - Exelixis, Inc.

37.41 -0.31 -0.82

Exelixis, Inc.

Exelixis, Inc.

About

Profile

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following earl


Headquarters

Alameda, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

EXEL



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Exelixis Non-GAAP EPS of $0.10 misses by $0.09, revenue of $471.92M misses by $1.47M
  • Exelixis Q3 2023 Earnings Preview
  • Exelixis gains as Cabometyx patent trial ends (update)
  • Exelixis slumps amid Cabometyx patent trial (update)
  • Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors
  • Exelixis started at buy at Wainwright on targeted oncology pipeline
  • Exelixis inks licensing deal with Insilico for tumor candidate
  • Exelixis reports positive results for Cabometyx in pancreatic cancer type
  • Exelixis appoints Amy Peterson as Chief Medical Officer
  • Exelixis lead product hits main goal in Phase 3 prostate cancer trial
  • Exelixis Non-GAAP EPS of $0.31 beats by $0.09, revenue of $469.85M beats by $25.02M
  • Exelixis Q2 2023 Earnings Preview
  • Exelixis, Teva settle patent dispute over cancer drug Cabometyx
  • Exelixis sees three Farallon nominees elected to board
  • Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
  • Exelixis Non-GAAP EPS of $0.16 misses by $0.06, revenue of $408.8M misses by $13.86M
  • Exelixis Q1 2023 Earnings Preview
  • Exelixis board member resigns; Farallon gets third board seat in victory
  • Exelixis holder Farallon files definitive materials in proxy battle
  • Exelixis supports two of Farallon's board nominees as it faces proxy fight
Date Price Open High Low Vol Change
Dec 4 44.36 43.97
44.77
43.95
2.0M 0.80%
Dec 3 44.01 43.97
44.48
43.47
2.7M 1.31%
Dec 2 43.44 43.77
43.97
43
2.2M 0.02%
Dec 1 43.43 43.85
44.11
43.33
2.5M -1.68%
Nov 28 44.17 44.91
44.91
44.09
1.5M -0.09%
 
Nov 26 44.21 43.03
44.44
42.96
2.1M 2.50%
Nov 25 43.13 42.5
43.59
42.25
2.9M 2.08%
Nov 24 42.25 42.31
43
42.15
4.5M -0.61%
Nov 21 42.51 42.08
42.86
41.82
2.8M 1.75%
Nov 20 41.78 42.32
42.5
41.69
2.3M -0.85%
Nov 19 42.14 42.95
42.99
41.65
2.2M -1.2%
Nov 18 42.65 41.76
42.74
41.76
2.0M 0.54%
Nov 17 42.42 41.58
43.16
41.58
2.3M 1.85%
Nov 14 41.65 41.93
42.59
41.23
2.6M -1.65%
Nov 13 42.35 43.09
43.72
42.18
3.1M -2.84%
Nov 12 43.59 42.98
43.68
42.62
2.4M 1.44%
Nov 11 42.97 41.44
43.22
41.44
2.9M 3.77%
Nov 10 41.41 41.03
41.54
39.83
2.6M 1.47%
Nov 7 40.81 40.63
40.83
39.93
2.3M 0.02%
Nov 6 40.8 40.05
41.21
40.05
2.9M 1.07%
Nov 5 40.37 40
41.54
38.19
5.0M 6.52%
Nov 4 37.9 37.81
38.9
37.58
3.5M -0.42%
Nov 3 38.06 37.55
38.41
36
4.5M -1.58%
Oct 31 38.67 38.62
38.96
38.25
2.1M -0.69%
Oct 30 38.94 39.48
39.76
38.92
2.2M -1.24%
Oct 29 39.43 40.01
40.24
39.38
1.9M -1.62%
Oct 28 40.08 40.01
40.63
39.45
2.0M 0.23%
Oct 27 39.99 39.04
40.02
38.91
2.3M 3.28%
Oct 24 38.72 38
39.15
37.82
2.4M 1.76%
Oct 23 38.05 36.27
38.33
36.08
3.9M 5.46%
Oct 22 36.08 36.02
36.45
35.44
3.1M -0.14%
Oct 21 36.13 35.05
36.13
34.63
5.6M 4.60%
Oct 20 34.54 35.55
36.17
33.76
9.4M -12%
Oct 17 39.25 39.33
39.6
38.62
2.2M 0.10%
Oct 16 39.21 39.99
40.05
39.06
1.9M -2.05%
Oct 15 40.03 39.53
40.54
39.46
1.9M 1.32%
Oct 14 39.51 38.46
39.9
38.18
3.1M 2.78%
Oct 13 38.44 38.36
38.79
37.52
2.2M 0.76%
Oct 10 38.15 38.67
38.71
37.71
2.9M -1.09%
Oct 9 38.57 38.91
39.09
38.27
1.7M -0.18%
Oct 8 38.64 39.42
39.48
38.59
3.1M -2.5%
Oct 7 39.63 40.15
40.2
38.98
2.1M -0.95%
Oct 6 40.01 40.29
40.43
39.68
1.9M -0.2%
Oct 3 40.09 41.44
41.45
40.05
2.2M -3.05%
Oct 2 41.35 41.23
41.4
40.44
1.9M 0.36%
Oct 1 41.2 41.3
41.78
40.86
2.5M -0.24%
Sep 30 41.3 40.47
41.6
40.35
2.2M 1.80%
Sep 29 40.57 39.17
40.6
39
2.5M 3.92%
Sep 26 39.04 38.73
39.24
38.57
1.6M 0.90%
Sep 25 38.69 38.83
38.91
38.35
1.8M -0.57%
Sep 24 38.91 39.7
39.99
38.56
2.0M -2.26%
Sep 23 39.81 39.59
39.96
39.47
1.5M 0.58%
Sep 22 39.58 40
40.66
39.55
2.1M -1.3%
Sep 19 40.1 40.24
40.55
39.87
7.8M -0.87%
Sep 18 40.45 40.54
40.59
39.9
2.8M 0.02%
Sep 17 40.44 39.66
40.78
39.32
2.7M 3.32%
Sep 16 39.14 39.09
39.57
38.61
1.7M 0.33%
Sep 15 39.01 39.12
39.17
38.37
2.3M -0.36%
Sep 12 39.15 38.73
39.27
38.59
2.5M 0.20%
Sep 11 39.07 37.78
39.09
37.57
2.6M 0%